In a long-term follow-up of a phase 2 clinical trial, veterans, firefighters, and police officers with chronic, treatment-resistant PTSD reported lasting personal benefits and enhanced quality of life one year after MDMA-assisted psychotherapy. Interviews with 19 of 24 participants were analyzed using interpretative phenomenological analysis. All participants described benefits that went beyond symptom reduction, such as improved relationships and well-being. The findings suggest that qualitative methods can capture treatment effects that standard symptom scales may miss. The authors discuss limitations of the study and recommend improved qualitative research protocols for future trials.
Anxiety related to life-threatening illness is a common problem that current treatments only partially address. In a pilot clinical trial of MDMA-assisted therapy for this condition, participants described key therapeutic experiences: processing trauma and grief, having mystical and existential experiences, engaging more fully with the present moment with less physiological arousal, and facing fears about illness and death. Outcomes included better ability to cope with their illness, reduced psychological symptoms, improved vitality and quality of life, and greater emotional resilience even after medical relapse. The findings suggest that MDMA-assisted therapy may help people reconnect to life and build emotional resources for dealing with existential distress.